CompletedNot Applicable

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

United States140,706 participantsStarted 2019-07-01

Plain-language summary

The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of RA or PsA * ≥18 years at index treatment initiation * Participants starting treatment with: * abatacept * non-targeted DMARDs * targeted DMARD Exclusion Criteria: \- Not applicable

What they're measuring

Incidence Rate of Overall Malignancies

Timeframe: 5 years

Incidence Rate of Melanoma

Timeframe: 5 years

Incidence Rate of Non-melanoma Skin Cancer

Timeframe: 5 years

Incidence Rate of Basal Cell Carcinoma

Timeframe: 5 years

Incidence Rate of Squamous Cell Carcinoma

Timeframe: 5 years

Trial details

NCT IDNCT05413044

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-08-22

View on ClinicalTrials.gov More Rheumatoid Arthritis trials